Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19.
Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19.
复制标题
DOI：
10.1002/art.41593
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Haroon S
中科院分区：
文献类型：
--
作者：
Chandan JS;Zemedikun DT;Thayakaran R;Byne N;Dhalla S;Acosta-Mena D;Gokhale KM;Thomas T;Sainsbury C;Subramanian A;Cooper J;Anand A;Okoth KO;Wang J;Adderley NJ;Taverner T;Denniston AK;Lord J;Thomas GN;Buckley CD;Raza K;Bhala N;Nirantharakumar K;Haroon S
确定与使用其他常见镇痛药相比，积极使用非甾体类抗炎药（NSAID）是否会增加发生疑似或确诊的2019冠状病毒病（COVID-19）的易感性。我们使用一个大型的英国初级保健数据集，进行了一项与活性对照药物的倾向评分匹配队列研究。该队列由2020年1月30日至7月31日随访的年龄≥18岁的骨关节炎（OA）成人患者组成。将处方NSAID（不包括局部制剂）的患者与处方co-codamol（对乙酰氨基酚和可待因）或co-dydramol（对乙酰氨基酚和双氢可待因）的患者进行比较。共确定了13，202例处方NSAID的患者，相比之下，12，457例患者处方了对照药物。主要结局指标是疑似或确诊COVID-19的记录，次要结局指标是全因死亡率。随访期间，NSAID暴露组和对照组中疑似/确诊COVID-19的发生率分别为15.4和19.9/1000人年。使用初级保健机构临床咨询的数据，在不匹配和倾向评分匹配的OA队列中，疑似或确诊COVID-19的调整后风险比为0.82（95%置信区间[95% CI] 0.62-1.10）和0.79（95% CI 0.57-1.11），全因死亡风险的校正风险比为0.97（95% CI 0.75-1.27）和0.85（95% CI 0.61-1.20）。年龄或性别对效应无影响。与接受对照药物的患者相比，在初级保健环境中接受NSAID处方的OA患者中未观察到疑似或确诊COVID-19或死亡率的风险增加。这些结果令人放心，并表明在没有急性疾病的情况下，NSAID可以在正在进行的大流行期间安全地处方。
To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID‐19) compared to the use of other common analgesics. We performed a propensity score–matched cohort study with active comparators, using a large UK primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to those prescribed either co‐codamol (paracetamol and codeine) or co‐dydramol (paracetamol and dihydrocodeine). A total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator drugs. The primary outcome measure was the documentation of suspected or confirmed COVID‐19, and the secondary outcome measure was all‐cause mortality. During follow‐up, the incidence rates of suspected/confirmed COVID‐19 were 15.4 and 19.9 per 1,000 person‐years in the NSAID‐exposed group and comparator group, respectively. Adjusted hazard ratios for suspected or confirmed COVID‐19 among the unmatched and propensity score–matched OA cohorts, using data from clinical consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62–1.10) and 0.79 (95% CI 0.57–1.11), respectively, and adjusted hazard ratios for the risk of all‐cause mortality were 0.97 (95% CI 0.75–1.27) and 0.85 (95% CI 0.61–1.20), respectively. There was no effect modification by age or sex. No increase in the risk of suspected or confirmed COVID‐19 or mortality was observed among patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be safely prescribed during the ongoing pandemic.
登录
查看更多内容
影响因子：
158.5
作者：
Galiè, N;Ghofrani, HA;Simonneau, G
通讯作者：
Simonneau, G
影响因子：
24.3
作者：
Hoeper, Marius M.;Kramer, Tilmann;Gruenig, Ekkehard
通讯作者：
Gruenig, Ekkehard
影响因子：
27.4
作者：
Humbert M;Coghlan JG;Ghofrani HA;Grimminger F;He JG;Riemekasten G;Vizza CD;Boeckenhoff A;Meier C;de Oliveira Pena J;Denton CP
通讯作者：
Denton CP
DOI：
10.1002/art.41669
发表时间：
2021-05
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
Khanna D;Zhao C;Saggar R;Mathai SC;Chung L;Coghlan JG;Shah M;Hartney J;McLaughlin V
通讯作者：
McLaughlin V
影响因子：
9.6
作者：
Benza, Raymond L.;Miller, Dave P.;McGoon, Michael D.
通讯作者：
McGoon, Michael D.